TY - JOUR
T1 - Tumor-targeting salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice
AU - Hiroshima, Yukihiko
AU - Zhao, Ming
AU - Zhang, Yong
AU - Zhang, Nan
AU - Maawy, Ali
AU - Murakami, Takashi
AU - Mii, Sumiyuki
AU - Uehara, Fuminari
AU - Yamamoto, Mako
AU - Miwa, Shinji
AU - Yano, Shuya
AU - Momiyama, Masashi
AU - Mori, Ryutaro
AU - Matsuyama, Ryusei
AU - Chishima, Takashi
AU - Tanaka, Kuniya
AU - Ichikawa, Yasushi
AU - Bouvet, Michael
AU - Endo, Itaru
AU - Hoffman, Robert M.
N1 - Publisher Copyright:
Copyright: © 2015 Hiroshima et al.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/8/3
Y1 - 2015/8/3
N2 - A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemoresistant soft-tissue sarcoma.
AB - A patient-derived nude-mouse model of soft-tissue sarcoma has been established and treated in the following groups: (1) untreated controls; (2) gemcitabine (GEM) (80 mg/kg, ip, weekly, 3 weeks); (3) Pazopanib (100 mg/kg, orally, daily, 3 weeks) and (4) Salmonella typhimurium A1-R (5 × 107 CFU/body, ip, weekly, 3 weeks). The sarcoma was resistant to GEM (p = 0.879). Pazopanib tended to reduce the tumor volume compared to the untreated mice, but there was no significant difference (p = 0.115). S. typhimurium A1-R significantly inhibited tumor growth compared to the untreated mice (p = 0.001). S. typhimurium A1-R was the only effective treatment for the soft-tissue sarcoma nude mouse model among all treatments including a newly approved multiple tyrosine kinase inhibitor; Pazopanib. These results suggest tumor-targeting S. typhimurium A1-R is a promising treatment for chemoresistant soft-tissue sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=84942103142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942103142&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0134324
DO - 10.1371/journal.pone.0134324
M3 - Article
C2 - 26237416
AN - SCOPUS:84942103142
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 8
M1 - e0134324
ER -